CompletedPhase 2NCT00003352
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NSABP Foundation Inc
- Principal Investigator
- Norman Wolmark, MDNSABP Foundation Inc
- Intervention
- cyclophosphamide(drug)
- Enrollment
- 89 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 1998 – 2002
Study locations (30)
- Baptist Medical Center - Birmingham, Birmingham, Alabama, United States
- Huntsville Hospital System, Huntsville, Alabama, United States
- MBCCOP - University of South Alabama, Mobile, Alabama, United States
- CCOP - Greater Phoenix, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Beckman Research Institute, City of Hope, Duarte, California, United States
- Scripps Clinic and Research Foundation - La Jolla, La Jolla, California, United States
- University of California San Diego Cancer Center, La Jolla, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Saint Mary Medical Center - Long Beach, Long Beach, California, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- Naval Medical Center - Oakland, Oakland, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- Veterans Affairs Satellite Clinic - Sacramento, Sacramento, California, United States
- Naval Medical Center - San Diego, San Diego, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003352 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University